Micro-ultrasound-targeted biopsy enables the detection of minimal-extent prostate adenocarcinoma (≤ 1 mm): clinicopathological findings from a consecutive series

Authors

  • Adriana Rodríguez-Gómez Laboratorio InmunoQ, Ciudad de México, México
  • Laura Guadalupe Hernández-González Laboratorio InmunoQ, Ciudad de México, México
  • Leticia Bornstein-Quevedo Laboratorio InmunoQ, Ciudad de México, México
  • Jesús David Castrejón-García Urodiagnóstico México, Ciudad de México, México
  • José de Jesús Castañeda-Sánchez Urodiagnóstico México, Ciudad de México, México

DOI:

https://doi.org/10.48193/xx85hx78

Keywords:

prostatic acinar adenocarcinoma, prostate cáncer, minimal tumor extent, micro-ultrasound, prostate biopsy

Abstract

Objective: To determine the frequency and clinicopathological characteristics of cases of minimal-extent prostate adenocarcinoma (linear extent ≤ 1 mm) identified in prostate biopsies performed using micro-ultrasound (Micro-US).

Materials and methods: This retrospective, observational, descriptive study included 604 unique patients who underwent prostate biopsy using an approach incorporating micro-ultrasound (Micro-US) between January 2024 and December 2025.

Patients were included if a single focus of prostatic acinar adenocarcinoma with a maximum linear extent of ≤1 mm was identified in the examined biopsy cores. Case selection was based on the maximum linear extent of the tumor focus, as measured histologically.

Results: Twelve cases of minimal-extent prostatic acinar adenocarcinoma were identified among the 604 patients studied. Ten cases (83.3 %) were detected in targeted biopsy cores and two (16.7 %) in systematic biopsy cores. The mean patient age was 64.3 years, and the median prostate-specific antigen (PSA) level was 6.3 ng/mL. The mean linear extent of adenocarcinoma was 0.74 mm (range, 0.12–1.0 mm). Multiparametric magnetic resonance imaging was available in three cases, with findings classified as PI-RADS 3 in one case and PI-RADS 4 in the remaining two.

Conclusions: Minimal-extent prostatic acinar adenocarcinoma (≤ 1 mm) was identified in 1.99 % (12/604) of the patients. Most cases were detected in targeted biopsy cores. The identification of these minimal-extent foci highlights that very small-volume tumors can be recognized histopathologically in prostate biopsies obtained using procedures incorporating Micro-US.

References

1. Epstein JI, Netto GJ. Biopsy Interpretation of the Prostate. Lippincott Williams & Wilkins; 2008.

2. Liu Z, Wu J, Lu Q, Li Y, Yang Y. Evolution of the prostate cancer diagnostic paradigm: integrated evidence and clinical pathways from targeted biopsy to biopsy-free strategy. Frontiers in Oncology. 2026;16. https://doi.org/10.3389/fonc.2026.1835580.

3. Labra W. A, Zúñiga G. Á, Labra W. A, Zúñiga G. Á. Pitfalls en RM de Próstata Multiparamétrica. Revista chilena de radiología. 2019;25(4): 128–140. https://doi.org/10.4067/S0717-93082019000400128.

4. Becerra CAG, Gallardo MIA, Juárez-García JE, Soltero-Molinar V, Rivera-Rocha MI, Luis F. Parra-Camaño, et al. Precisión diagnóstica de la resonancia magnética multiparamétrica en cáncer de próstata: revisión sistemática y metaanálisis bivariado de 4954 pacientes. Revista Mexicana de Urología. 2025;85(6): 1–14. https://doi.org/10.48193/s7g2sh54.

5. Klotz L, Lughezzani G, Maffei D, Sánchez A, Pereira JG, Staerman F, et al. Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer: A multicenter, prospective analysis. Canadian Urological Association Journal = Journal De l’Association Des Urologues Du Canada. 2021;15(1): E11–E16. https://doi.org/10.5489/cuaj.6712.

6. Ghai S, Eure G, Fradet V, Hyndman ME, McGrath T, Wodlinger B, et al. Assessing Cancer Risk on Novel 29 MHz Micro-Ultrasound Images of the Prostate: Creation of the Micro-Ultrasound Protocol for Prostate Risk Identification. Journal of Urology. 2016;196(2): 562–569. https://doi.org/10.1016/j.juro.2015.12.093.

7. Micheleto JPC, Suzuki TÁ, Santos LA, Sales LP, Lopes RI, Martins BM, et al. Micro-ultrasonography- vs MRI-targeted biopsy in prostate cancer: Updated systematic review and meta-analysis. BJU International. 2026;138(2): 196–207. https://doi.org/10.1111/bju.70270.

8. Kinnaird A, Luger F, Cash H, Ghai S, Urdaneta-Salegui LF, Pavlovich CP, et al. Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial. JAMA. 2025;333(19): 1679–1687. https://doi.org/10.1001/jama.2025.3579.

9. Thorson P, Humphrey PA. Minimal adenocarcinoma in prostate needle biopsy tissue. American Journal of Clinical Pathology. 2000;114(6): 896–909. https://doi.org/10.1309/KVPX-C1EM-142L-1M6W.

10. Leroy X, Aubert S, Villers A, Ballereau C, Augusto D, Gosselin B. Minimal focus of adenocarcinoma on prostate biopsy: clinicopathological correlations. Journal of Clinical Pathology. 2003;56(3): 230–232. https://doi.org/10.1136/jcp.56.3.230.

11. Epstein JI. Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc. 2004;17(3): 307–315. https://doi.org/10.1038/modpathol.3800050.

12. Samaratunga H, Yaxley J, Kerr K, McClymont K, Duffy D. Significance of Minute Focus of Adenocarcinoma on Prostate Needle Biopsy. Urology. 2007;70(2): 299–302. https://doi.org/10.1016/j.urology.2007.03.068.

13. Srigley JR. Benign mimickers of prostatic adenocarcinoma. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc. 2004;17(3): 328–348. https://doi.org/10.1038/modpathol.3800055.

14. Kane CJ, Im R, Amling CL, Presti JC, Aronson WJ, Terris MK, et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology. 2010;76(3): 695–700. https://doi.org/10.1016/j.urology.2009.12.073.

15. Garisto JD, Klotz L. Active surveillance for prostate cancer: how to do it right. Oncology (Williston Park). 2017;31(5): 333–340.

16. Singh V, Manu V, Malik A, Dutta V, Mani NS, Patrikar S. Diagnostic utility of p63 and α-methyl acyl Co A racemase in resolving suspicious foci in prostatic needle biopsy and transurethral resection of prostate specimens. Journal of Cancer Research and Therapeutics. 2014;10(3): 686–692. https://doi.org/10.4103/0973-1482.138194.

17. Jiang Z, Li C, Fischer A, Dresser K, Woda BA. Using an AMACR (P504S)/34βE12/p63 Cocktail for the Detection of Small Focal Prostate Carcinoma in Needle Biopsy Specimens. American Journal of Clinical Pathology. 2005;123(2): 231–236. https://doi.org/10.1309/1G1NK9DBGFNB792L.

18. Aljoulani M, Buffi NM, Lughezzani G, Rai B, Hanchanale V, O’Leary A, et al. Micro-ultrasound in the diagnostic pathway of prostate cancer: Emerging roles in initial detection and active surveillance. Journal of Clinical Urology. 2026;19(5): 451–462. https://doi.org/10.1177/20514158261463586.

Downloads

Published

2026-11-12

Data Availability Statement

Los datos que respaldan los hallazgos de este estudio están disponibles a solicitud razonable al autor de correspondencia. Debido a restricciones relacionadas con la privacidad y confidencialidad de los pacientes, los datos no se encuentran disponibles públicamente.

Issue

Section

Original articles